Rocket Pharmaceuticals (RCKT) Non-Current Assets (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Non-Current Assets data on file, last reported at $135.6 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 7.5% year-over-year to $135.6 million; the trailing twelve-month figure through Mar 2026 stood at $557.5 million (down 7.35% YoY), and the FY2025 full-year result was $137.7 million, down 7.89% from the prior year.
• Non-Current Assets fell to $135.6 million in Q1 2026, from $137.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $188.1 million in Q4 2023 to a low of -$445.2 million in Q3 2023.
• A 5-year average of -$22.9 million and a median of $140.4 million in 2025 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets slumped 43.9% in 2023 and jumped 149.45% in 2024, its largest moves.
• Tracing RCKT's Non-Current Assets over 5 years: stood at $187.7 million in 2022, then grew by 0.2% to $188.1 million in 2023, then slipped by 20.52% to $149.5 million in 2024, then dropped by 7.89% to $137.7 million in 2025, then decreased by 1.55% to $135.6 million in 2026.
• Business Quant data shows RCKT's Non-Current Assets at $135.6 million in Q1 2026, $137.7 million in Q4 2025, and $140.4 million in Q3 2025.